^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HDAC10 inhibitor

    Associations

    News

    Trials
    8ms
    Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma. (PubMed, Clin Epigenetics)
    Concurrently, the combined regimen enhanced their respective anticancer effects by inhibiting the key genes HDAC10 and BCL-xL. Taken together, venetoclax combined with chidamide presents a potent anticancer strategy in preclinical models of t-FL and merits further exploration in clinical trials to validate its effectiveness and safety for treating t-FL.
    Preclinical • Journal • IO biomarker
    |
    BCL2L1 (BCL2-like 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HDAC10 (Histone Deacetylase 10)
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    8ms
    QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • Epidaza (chidamide) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8ms
    Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (clinicaltrials.gov)
    P3, N=224, Not yet recruiting, Chipscreen Biosciences, Ltd.
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    8ms
    Rituximab-Chidamide combination chemotherapy enhances autophagy to overcome drug resistance in diffuse large B-cell lymphoma. (PubMed, Int Immunopharmacol)
    These findings suggest that the BTG1/BECN1/ATG5 signaling axis plays a critical role in enhancing autophagy and reversing Rituximab resistance. The combination of Chidamide and Rituximab presents a promising therapeutic strategy, offering new insights into overcoming drug resistance in DLBCL.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • ATG5 (Autophagy Related 5) • BECN1 (Beclin 1) • MAPK8 (Mitogen-activated protein kinase 8) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)
    |
    Rituxan (rituximab) • Epidaza (chidamide)
    9ms
    Chidamide-REAC in autologous stem cell transplantation of high-risk or relapsed/refractory B-cell lymphoma (ChiCTR2500098425)
    P=N/A, N=30, Recruiting, Dongguan Kanghua Hospital; Dongguan Kanghua Hospital
    New trial
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Epidaza (chidamide)
    9ms
    A single arm multicenter clinical study of Zanubrutinib combined with Chidamide and Rituximab for first-line treatment of elderly patients with double expression diffuse large B-cell lymphoma (ChiCTR2500098804)
    P2, N=50, Recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • MYC rearrangement + BCL6 rearrangement
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    9ms
    Cadonilimab in Combination with Chemotherapy and Chidamide as First-Line Treatment of Advanced Gastric Cancer (ChiCTR2500096832)
    P2, N=42, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    capecitabine • albumin-bound paclitaxel • oxaliplatin • Epidaza (chidamide) • Kaitanni (cadonilimab)
    9ms
    Phase II Clinical Study of the Efficacy and Safety of Chidamide and Anlotinib in Combination with AG Regimen in Patients with Advanced or Recurrent Pancreatic Cancer (ChiCTR2500095869)
    P2, N=223, Not yet recruiting, The Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University
    New P2 trial
    |
    Focus V (anlotinib) • Epidaza (chidamide)
    9ms
    PI3Kδ Inhibitor Parsaclisib Combined with Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=12, Terminated, Henan Cancer Hospital | N=28 --> 12 | Trial completion date: Jan 2027 --> Feb 2025 | Recruiting --> Terminated; The clinical development of parsaclisib was stopped by it's manufacturer.
    Enrollment change • Trial completion date • Trial termination
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide) • parsaclisib (INCB50465)
    9ms
    Zanubrutinib, Chidamide, and Rituximab Induction with or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, Li Zhiming
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    9ms
    Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes (clinicaltrials.gov)
    P2, N=148, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Epidaza (chidamide)
    9ms
    Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL (clinicaltrials.gov)
    P2, N=22, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025
    Enrollment open • Trial initiation date
    |
    Epidaza (chidamide) • Columvi (glofitamab-gxbm)